{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:17:54Z","timestamp":1739942274545,"version":"3.37.3"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1124\/dmd.107.014894","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:24:51Z","timestamp":1180657491000},"page":"1603-1610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Effect of Silibinin on the Pharmacokinetics of Pyrazinamide and Pyrazinoic Acid in Rats"],"prefix":"10.1016","volume":"35","author":[{"given":"Jhy-Wen","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Hu","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.107.014894_bib1","first-page":"849","article-title":"Clinical pharmacokinetics and metabolism of pyrazinamide in healthy volunteers","volume":"37","author":"Bareggi","year":"1987","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/dmd.107.014894_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF03190223","article-title":"Pharmacokinetic studies on IdB 1016, a silybin phosphatidylcholine complex, in healthy human subjects","volume":"15","author":"Barzaghi","year":"1990","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.107.014894_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0378-4347(96)00088-6","article-title":"Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics","volume":"686","author":"Bressolle","year":"1996","journal-title":"J Chromatogr B"},{"key":"10.1124\/dmd.107.014894_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0165-0173(97)00014-3","article-title":"Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier","volume":"25","author":"de Lange","year":"1997","journal-title":"Brain Res Rev"},{"key":"10.1124\/dmd.107.014894_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0041-3879(76)90046-5","article-title":"Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide","volume":"57","author":"Ellard","year":"1976","journal-title":"Tubercle"},{"key":"10.1124\/dmd.107.014894_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10637-006-9019-2","article-title":"A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients","volume":"25","author":"Flaig","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.107.014894_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1572-0241.1998.00139.x","article-title":"Milk thistle (Silybum marianum) for the therapy of liver disease","volume":"93","author":"Flora","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/dmd.107.014894_bib8","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/AAC.33.8.1252","article-title":"Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?","volume":"33","author":"Heifets","year":"1989","journal-title":"Antimicrob Agent Chemother"},{"key":"10.1124\/dmd.107.014894_bib9","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1086\/375072","article-title":"Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity","volume":"36","author":"Kunimoto","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.107.014894_bib10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1183\/09031936.93.01090807","article-title":"Interaction between allopurinol and pyrazinamide","volume":"1","author":"Lacroix","year":"1988","journal-title":"Eur Respir J"},{"key":"10.1124\/dmd.107.014894_bib11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/BF01062545","article-title":"In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models","volume":"10","author":"Lin","year":"1982","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.107.014894_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/bdd.305","article-title":"Investigation of the effects of concomitant caffeine administration on the metabolic disposition of pyrazinamide in rats","volume":"23","author":"Mehmedagic","year":"2002","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.107.014894_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1472-8206.1989.tb00449.x","article-title":"Prevention of CCL4-induced liver cirrhosis by silymarin","volume":"3","author":"Mourelle","year":"1989","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/dmd.107.014894_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/jat.2550120613","article-title":"Silymarin protects against paracetamol-induced lipid peroxidation and liver damage","volume":"12","author":"Muriel","year":"1992","journal-title":"J Appl Toxicol"},{"key":"10.1124\/dmd.107.014894_bib15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/ajhp\/56.12.1195","article-title":"Milk thistle: Silybum marianum","volume":"56","author":"Pepping","year":"1999","journal-title":"Am J Health Syst Pharm"},{"key":"10.1124\/dmd.107.014894_bib16","first-page":"109","article-title":"Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole","volume":"54","author":"Rajnarayana","year":"2004","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/dmd.107.014894_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1023\/A:1018971818689","article-title":"In vivo microdialysis sampling in the bile, blood, and liver of rats to study the disposition of phenol","volume":"10","author":"Scott","year":"1993","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.107.014894_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/0002-9343(57)90230-9","article-title":"Hyperuricemia due to pyrazinamide","volume":"23","author":"Shapiro","year":"1957","journal-title":"Am J Med"},{"key":"10.1124\/dmd.107.014894_bib19","first-page":"263","article-title":"Inhibition of xanthine oxidase by purpurogallin and silymarin group","volume":"18","author":"Sheu","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1124\/dmd.107.014894_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/pgmj.71.836.359","article-title":"Antituberculosis treatment-induced hepatotoxicity: role of predictive factors","volume":"71","author":"Singh","year":"1995","journal-title":"Postgrad Med J"},{"key":"10.1124\/dmd.107.014894_bib21","first-page":"1091","article-title":"Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin","volume":"130","author":"Snider","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"10.1124\/dmd.107.014894_bib22","first-page":"136","article-title":"Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy","volume":"14","author":"Solangi","year":"2004","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1124\/dmd.107.014894_bib23","first-page":"70","article-title":"The absorption and excretion of pyrazinamide. I. Preliminary study in laboratory animals and in man","volume":"98","author":"Stottmeier","year":"1968","journal-title":"Am Rev Respir Dis"},{"key":"10.1124\/dmd.107.014894_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.hepres.2005.01.005","article-title":"Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin","volume":"31","author":"Tasduq","year":"2005","journal-title":"Hepatol Res"},{"key":"10.1124\/dmd.107.014894_bib25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000220356","article-title":"Comparison of the antituberculous activity of morphazinamide and pyrazinamide on chronic experimental tuberculosis. I. The antimycobacterial efficacy made in vitro and in vivo","volume":"9","author":"Trnka","year":"1964","journal-title":"Chemotherapy"},{"key":"10.1124\/dmd.107.014894_bib26","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.bjp.0703927","article-title":"Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis","volume":"132","author":"Tsai","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.107.014894_bib27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.bjp.0704363","article-title":"Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis","volume":"134","author":"Tsai","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.107.014894_bib28","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/0006-2952(85)90421-6","article-title":"Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat","volume":"34","author":"Valenzuela","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.107.014894_bib29","first-page":"1028","article-title":"Tuberculous meningitis: is a 6-month treatment regimen sufficient?","volume":"5","author":"van Loenhout-Rooyackers","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1124\/dmd.107.014894_bib30","first-page":"466","article-title":"The chemistry and analysis of silymarin from Silybum marianum Gaertn","volume":"24","author":"Wagner","year":"1974","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/dmd.107.014894_bib31","first-page":"688","article-title":"On the chemistry of silymarin (silybin), the active principle of the fruits from Silybum marianum (L.) Gaertn. (Carduus marianus L.)","volume":"18","author":"Wagner","year":"1968","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/dmd.107.014894_bib32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-3565(25)29122-4","article-title":"Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention","volume":"180","author":"Weiner","year":"1972","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.014894_bib33","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/dmd.107.014894_bib34","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1093\/carcin\/20.11.2101","article-title":"Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention","volume":"20","author":"Zhao","year":"1999","journal-title":"Carcinogenesis"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624014193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624014193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.107.014894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:23:05Z","timestamp":1739895785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624014193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0090955624014193"],"URL":"https:\/\/doi.org\/10.1124\/dmd.107.014894","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Silibinin on the Pharmacokinetics of Pyrazinamide and Pyrazinoic Acid in Rats","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.107.014894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}